New Delhi: China is testing a brain-computer interface that could be implanted through blood vessels in the neck without requiring doctors to open the skull. The experimental approach, being developed by Shanghai-based StairMed Technology with researchers from the Chinese Academy of Sciences, could make brain implants significantly less invasive if it proves safe and effective in human trials.

The technology is part of China’s growing push into brain-computer interfaces (BCIs), a field that aims to translate electrical signals generated by the brain into commands that computers and other electronic devices can understand. Such systems could eventually help people with severe paralysis communicate, control digital devices and regain some independence.

However, despite the attention surrounding the reported 10-minute implantation time, the technology remains experimental. StairMed has so far tested its procedure on sheep and has not yet begun human trials. A separate vascular BCI programme in China has already reached human testing, highlighting the country’s broader efforts to develop less invasive neural technologies.

How China’s skull-free brain implant works

Traditional brain-computer interfaces generally require invasive surgery. Doctors may need to open the skull and position electrodes directly on or inside the brain to capture neural activity.

StairMed’s approach attempts to avoid that step by using the body’s existing network of blood vessels as a pathway. According to the report, doctors would insert the device through a blood vessel in the neck and guide it through the vascular system towards a targeted region of the brain. The implant can then be positioned outside the blood vessel wall.

The concept could represent a major change in how BCIs are implanted. Instead of performing open brain surgery, physicians could potentially access the brain through a vascular route, reducing the physical trauma associated with conventional implantation.

The approach is not entirely new. US-based Synchron has also developed a BCI that is delivered through the jugular vein, with implants carried out in patients in Australia and the United States. This means researchers in several countries are exploring whether blood vessels can provide a safer and less invasive route for brain-computer interfaces.

10-minute procedure is still an experimental target

One of the most striking claims surrounding the Chinese technology is the possibility of positioning the implant in about 10 minutes.

Duan Wanru, chief physician at Xuanwu Hospital under Beijing’s Capital Medical University, said a surgeon with four or five years of experience could position the device in as little as 10 minutes. He also said researchers had not encountered major safety concerns in their work and that the implant could potentially be removed within a month of the procedure.

But the reported time should not be interpreted as evidence that a 10-minute BCI procedure is already available to patients.

StairMed’s own system has so far only been tested on sheep. The company has not yet started human trials. As a result, researchers still need to establish whether the procedure can be performed reliably in people and whether the implant can remain stable while producing useful brain signals over longer periods.

Animal studies can provide important information about the safety and feasibility of a medical technology, but they cannot establish how an implant will behave in humans. Human clinical trials will therefore be an important next step before the technology can be considered for wider medical use.

China is expanding its BCI programme

The new technology is part of a broader effort by China to build a domestic brain-computer interface industry.

China’s Nankai University completed what it described as the world’s first human trial of a BCI implanted through blood vessels last year. Separately, researchers at Xuanwu Hospital have begun a human clinical study involving a vascular approach using the brain’s venous sinuses.

Beijing has also set an ambition of developing two or three globally competitive companies in the BCI sector by 2030. The government and private investors are consequently putting increasing resources into neurotechnology, an area that combines medicine, artificial intelligence, electronics and neuroscience.

StairMed itself has reportedly attracted more than 1.1 billion yuan in funding over the past year, with Alibaba and Tencent among its investors. The company has already demonstrated one potential application of its technology through a patient using a surgically implanted BCI to interact with Chinese e-commerce platform JD.com and reportedly earn about 1,800 yuan a month.

What could brain-computer interfaces do?

The long-term promise of BCIs extends well beyond simply connecting a computer to the brain.

The basic idea is to detect electrical activity generated by the brain and translate those signals into commands. For someone who cannot move their limbs, for example, a BCI could potentially allow them to select letters, control a computer cursor or operate other connected devices using neural signals.

Such applications could be particularly important for people living with severe paralysis. Instead of relying entirely on physical movements to communicate or interact with technology, patients could potentially use brain activity to issue commands.

The technology could also eventually have applications in robotics, assistive devices and other forms of human-machine interaction. However, these possibilities remain dependent on researchers solving significant technical and medical challenges.

Safety and long-term reliability remain key questions

The biggest question surrounding vascular BCIs is not simply whether doctors can place them quickly, but whether they can work safely and reliably over extended periods.

A device travelling through blood vessels must be positioned accurately and remain stable. Researchers also need to ensure that it can record meaningful neural signals without creating serious complications.

There are additional questions about how consistently the system will work from one patient to another and whether signal quality will remain useful as time passes.

India Today reported that animal testing alone cannot establish whether the technology will perform effectively in humans. Human trials will have to determine whether doctors can accurately position the device, keep it stable and capture useful brain signals without causing serious complications.

This is particularly important because the brain is an exceptionally complex organ, while blood vessels are delicate structures where complications can have serious consequences.

A less invasive future for brain implants?

China’s experiment highlights how quickly BCI technology is moving beyond the traditional model of opening the skull to implant electrodes.

A vascular approach could eventually make brain-computer interfaces easier to implant and potentially accessible to a larger number of patients. If clinical trials demonstrate that the devices can be positioned safely, remain stable and provide reliable neural signals, the technology could become an important alternative to conventional surgical BCIs.

For now, however, the 10-minute figure should be viewed as an experimental milestone rather than a ready-to-use medical procedure. StairMed’s system has yet to enter human trials, and much more testing will be required before its safety and effectiveness can be established.

The development nevertheless represents another significant step in the race to create less invasive brain-computer interfaces, with China increasingly positioning itself as a major player in the emerging neurotechnology industry.